| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing aspirin and caffeine and dextropropoxyphene (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin and butalbital and caffeine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only buffered aspirin and caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only butalbital and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin and caffeine and dextropropoxyphene only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and caffeine and orphenadrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin and caffeine and paracetamol only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and caffeine and cinnamedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Ammonium chloride and caffeine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and codeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine and dihydrocodeine and paracetamol only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and ergotamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine and glucose only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and isometheptene and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and butalbital and caffeine and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine and paracetamol and salicylamide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
2 |
| Caffeine and sodium benzoate only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
2 |
| Aspirin and caffeine and dihydrocodeine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Butalbital and caffeine and codeine and paracetamol only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and codeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and dihydrocodeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine and ergotamine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and ergotamine in rectal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and sodium benzoate in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
2 |
| Product containing only caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine only product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and butalbital and caffeine and codeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and butalbital and caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and caffeine and dextropropoxyphene in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin and caffeine and dihydrocodeine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and caffeine and orphenadrine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin and caffeine and paracetamol only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only butalbital and caffeine and codeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only butalbital and caffeine and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
2 |
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
2 |
| Product containing precisely caffeine 650 microgram/1 milliliter and paracetamol 5 milligram/1 milliliter conventional release oral solution (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely caffeine 650 microgram/1 milliliter and paracetamol 5 milligram/1 milliliter conventional release oral solution (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine- and isometheptene- and paracetamol-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only caffeine and isometheptene and paracetamol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| The known quantity of intake in one day of caffeine from all sources. |
This attribute specifies the resulting output of the process characterized by the observed feature. |
False |
Caffeine |
Inferred relationship |
Some |
6 |
| The approximate quantity of intake in one day of caffeine from all sources. |
This attribute specifies the resulting output of the process characterized by the observed feature. |
False |
Caffeine |
Inferred relationship |
Some |
6 |
| Product containing precisely caffeine 100 milligram and ergotamine tartrate 1 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 25 mg and paracetamol 450 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely aspirin 250 milligram and caffeine 65 milligram and paracetamol 250 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine-induced anxiety disorder |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| The approximate quantity of intake in one day of caffeine from all sources. |
This attribute specifies an entity that the process which the property characterizes specifically acts on. |
False |
Caffeine |
Inferred relationship |
Some |
3 |
| The known quantity of intake in one day of caffeine from all sources. |
This attribute specifies an entity that the process which the property characterizes specifically acts on. |
False |
Caffeine |
Inferred relationship |
Some |
3 |
| Caffeine intake |
This attribute specifies an entity that the process which the property characterizes specifically acts on. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Headache due to caffeine withdrawal syndrome (finding) |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine anhydrous |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Caffeine |
Inferred relationship |
Some |
|
| Caffeine 32 mg and paracetamol 500 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 32 mg and paracetamol 500 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 25 mg and guaifenesin 100 mg and paracetamol 500 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine 25 mg and guaifenesin 100 mg and paracetamol 500 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine- and guaifenesin- and paracetamol-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Caffeine and guaifenesin and paracetamol only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Acetaminophen 500 mg and caffeine 30 mg and codeine phosphate 8 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Acetaminophen 500 mg and caffeine 30 mg and codeine phosphate 8 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 325 mg and caffeine 15 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin 325 mg and caffeine 15 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only aspirin and caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Aspirin- and caffeine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely brompheniramine maleate 3 milligram and caffeine 30 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely brompheniramine maleate 3 milligram and caffeine 30 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Brompheniramine- and caffeine- and paracetamol-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Brompheniramine and caffeine and paracetamol only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing only brompheniramine and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing brompheniramine and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely caffeine 30 milligram and codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Product containing precisely caffeine 30 milligram and codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| An episode of caffeine use that has caused clinically significant harm to a person's physical or mental health. Harm may be caused by the intoxicating effects of caffeine, the direct or secondary toxic effects on body organs and systems, or a harmful route of administration. |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
| Disorder characterized by the pattern and consequences of caffeine use leading to clinically significant impairment or distress both to physical or mental health of the user or others around the user. |
Causative agent (attribute) |
True |
Caffeine |
Inferred relationship |
Some |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]